drugset / Trial / NCT01032083
Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
Phase 4
Completed
62 enrolled
Imperial College London
King's College London · collabUniversity College, London · collabUniversity of Bristol · collabUniversity of Manchester · collabUniversity of Oxford · collabUniversity of Southampton · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative symptoms of schizophrenia over a year.
Timeline
- Start
- 2011-07
- Primary completion
- 2014-12
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Citalopram | Small molecule | 20 mg | — |
| Comparator | Citalopram | Small molecule | 40 mg | — |